Last 12 months
Inside the activity.
0 purchase rows · 2 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 2 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 18, 2025 Filed Feb 20, 2025 22:07 UTC |
Morrison SusanEVP & Chief Admin. Officer
|
Exercise / conversionCommon Stock | 474 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-25-000018 · wk-form4_1740089240.xml · nonDerivative · entry 3 Morrison Susan · CIK 0001582970 · EVP & Chief Admin. Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,480 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 18, 2025 Filed Feb 20, 2025 22:07 UTC |
Morrison SusanEVP & Chief Admin. Officer
|
Tax withholdingCommon Stock | 56 | $33.47 | $1,874.32 |
DisclosureSEC source: 0001438133-25-000018 · wk-form4_1740089240.xml · nonDerivative · entry 2 Morrison Susan · CIK 0001582970 · EVP & Chief Admin. Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,006 F1 · kind: Shares withheld by Tandem Diabetes Care, Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold. Read SEC document |
| February 18, 2025 Filed Feb 20, 2025 22:07 UTC |
Morrison SusanEVP & Chief Admin. Officer
|
Exercise / conversionCommon Stock | 163 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-25-000018 · wk-form4_1740089240.xml · nonDerivative · entry 1 Morrison Susan · CIK 0001582970 · EVP & Chief Admin. Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,062 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 18, 2025 Filed Feb 20, 2025 22:07 UTC |
Sheridan John FDirector · PRESIDENT & CEO
|
Exercise / conversionRestricted Stock Unit · Derivative | 5,472 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-25-000017 · wk-form4_1740089229.xml · derivative · entry 9 Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,358 Underlying: Common Stock · 5,472 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · security: Awarded on May 25, 2023 pursuant to the Tandem Diabetes Care, Inc. 2023 Long-Term Incentive Plan, as amended, and agreements related thereto (the 2023 Plan). F8 · derivative.exercise_price: Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan. F9 · derivative.exercise_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2024, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. F9 · derivative.expiration_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2024, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. Read SEC document |
| February 18, 2025 Filed Feb 20, 2025 22:07 UTC |
Sheridan John FDirector · PRESIDENT & CEO
|
Exercise / conversionRestricted Stock Unit · Derivative | 2,237 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-25-000017 · wk-form4_1740089229.xml · derivative · entry 8 Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,236 Underlying: Common Stock · 2,237 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · security: Awarded on May 25, 2022 pursuant to the 2013 Plan. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2013 Plan. F6 · derivative.exercise_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2023, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. F6 · derivative.expiration_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2023, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. Read SEC document |
| February 18, 2025 Filed Feb 20, 2025 22:07 UTC |
Sheridan John FDirector · PRESIDENT & CEO
|
Exercise / conversionRestricted Stock Unit · Derivative | 793 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-25-000017 · wk-form4_1740089229.xml · derivative · entry 7 Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 792 Underlying: Common Stock · 793 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Awarded on May 18, 2021 pursuant to the Tandem Diabetes Care, Inc. 2013 Stock Incentive Plan, as amended, and the agreements related thereto (the 2013 Plan). F3 · derivative.exercise_price: Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2013 Plan. F4 · derivative.exercise_date: RSU vest as to twenty-five percent (25%) of the total number of shares subject to the RSU on 5/15/2022, and the remaining shares shall vest in twelve (12) equal quarterly installments thereafter. F4 · derivative.expiration_date: RSU vest as to twenty-five percent (25%) of the total number of shares subject to the RSU on 5/15/2022, and the remaining shares shall vest in twelve (12) equal quarterly installments thereafter. Read SEC document |
| February 18, 2025 Filed Feb 20, 2025 22:07 UTC |
Sheridan John FDirector · PRESIDENT & CEO
|
Tax withholdingCommon Stock | 2,097 | $33.47 | $70,186.59 |
DisclosureSEC source: 0001438133-25-000017 · wk-form4_1740089229.xml · nonDerivative · entry 6 Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,657 F1 · kind: Shares withheld by Tandem Diabetes Care, Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold. Read SEC document |
| February 18, 2025 Filed Feb 20, 2025 22:07 UTC |
Sheridan John FDirector · PRESIDENT & CEO
|
Exercise / conversionCommon Stock | 5,472 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-25-000017 · wk-form4_1740089229.xml · nonDerivative · entry 5 Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,754 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 18, 2025 Filed Feb 20, 2025 22:07 UTC |
Sheridan John FDirector · PRESIDENT & CEO
|
Tax withholdingCommon Stock | 801 | $33.47 | $26,809.47 |
DisclosureSEC source: 0001438133-25-000017 · wk-form4_1740089229.xml · nonDerivative · entry 4 Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,282 F1 · kind: Shares withheld by Tandem Diabetes Care, Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold. Read SEC document |
| February 18, 2025 Filed Feb 20, 2025 22:07 UTC |
Sheridan John FDirector · PRESIDENT & CEO
|
Exercise / conversionCommon Stock | 2,237 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-25-000017 · wk-form4_1740089229.xml · nonDerivative · entry 3 Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,083 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 18, 2025 Filed Feb 20, 2025 22:07 UTC |
Sheridan John FDirector · PRESIDENT & CEO
|
Tax withholdingCommon Stock | 284 | $33.47 | $9,505.48 |
DisclosureSEC source: 0001438133-25-000017 · wk-form4_1740089229.xml · nonDerivative · entry 2 Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,846 F1 · kind: Shares withheld by Tandem Diabetes Care, Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold. Read SEC document |
| February 18, 2025 Filed Feb 20, 2025 22:07 UTC |
Sheridan John FDirector · PRESIDENT & CEO
|
Exercise / conversionCommon Stock | 793 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-25-000017 · wk-form4_1740089229.xml · nonDerivative · entry 1 Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,130 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 18, 2025 Filed Feb 20, 2025 22:06 UTC |
Carpenter RickChief Technology Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 1,438 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-25-000015 · wk-form4_1740089206.xml · derivative · entry 6 Carpenter Rick · CIK 0001513889 · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,185 Underlying: Common Stock · 1,438 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · security: Awarded on May 25, 2023 pursuant to the Tandem Diabetes Care, Inc. 2023 Long-Term Incentive Plan, as amended, and agreements related thereto (the 2023 Plan). F6 · derivative.exercise_price: Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan. F7 · derivative.exercise_date: RSU vest as to thiry-three percent (33%) of the total number of shares subject to the RSU on 5/15/2024, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. F7 · derivative.expiration_date: RSU vest as to thiry-three percent (33%) of the total number of shares subject to the RSU on 5/15/2024, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. Read SEC document |
| February 18, 2025 Filed Feb 20, 2025 22:06 UTC |
Carpenter RickChief Technology Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 595 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-25-000015 · wk-form4_1740089206.xml · derivative · entry 5 Carpenter Rick · CIK 0001513889 · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 596 Underlying: Common Stock · 595 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Awarded on May 25, 2022 pursuant to the Tandem Diabetes Care, Inc. 2013 Stock Incentive Plan, as amended, and the agreements related thereto (the 2013 Plan). F3 · derivative.exercise_price: Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2013 Plan. F4 · derivative.exercise_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2023, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. F4 · derivative.expiration_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2023, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. Read SEC document |
| February 18, 2025 Filed Feb 20, 2025 22:06 UTC |
Carpenter RickChief Technology Officer
|
Tax withholdingCommon Stock | 591 | $33.47 | $19,780.77 |
DisclosureSEC source: 0001438133-25-000015 · wk-form4_1740089206.xml · nonDerivative · entry 4 Carpenter Rick · CIK 0001513889 · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,132 F1 · kind: Shares withheld by Tandem Diabetes Care, Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold. Read SEC document |
| February 18, 2025 Filed Feb 20, 2025 22:06 UTC |
Carpenter RickChief Technology Officer
|
Exercise / conversionCommon Stock | 1,438 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-25-000015 · wk-form4_1740089206.xml · nonDerivative · entry 3 Carpenter Rick · CIK 0001513889 · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,723 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 18, 2025 Filed Feb 20, 2025 22:06 UTC |
Carpenter RickChief Technology Officer
|
Tax withholdingCommon Stock | 245 | $33.47 | $8,200.15 |
DisclosureSEC source: 0001438133-25-000015 · wk-form4_1740089206.xml · nonDerivative · entry 2 Carpenter Rick · CIK 0001513889 · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,285 F1 · kind: Shares withheld by Tandem Diabetes Care, Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold. Read SEC document |
| February 18, 2025 Filed Feb 20, 2025 22:06 UTC |
Carpenter RickChief Technology Officer
|
Exercise / conversionCommon Stock | 595 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-25-000015 · wk-form4_1740089206.xml · nonDerivative · entry 1 Carpenter Rick · CIK 0001513889 · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,530 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 16, 2024 Filed Dec 18, 2024 21:57 UTC |
Novara Mark DavidEVP & CHIEF COMMERCIAL OFFICER
|
Exercise / conversionRestricted Stock Unit · Derivative | 29,658 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-24-000221 · wk-form4_1734559026.xml · derivative · entry 3 Novara Mark David · CIK 0002000342 · EVP & CHIEF COMMERCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,317 Underlying: Common Stock · 29,658 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Awarded on December 15, 2023 pursuant to the Tandem Diabetes Care, Inc. 2023 Long-Term Incentive Plan, as amended, and agreements related thereto (the 2023 Plan). F3 · derivative.exercise_price: Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan. F4 · derivative.exercise_date: RSU vest as to thiry-three percent (33%) of the total number of shares subject to the RSU on 12/15/2024, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. F4 · derivative.expiration_date: RSU vest as to thiry-three percent (33%) of the total number of shares subject to the RSU on 12/15/2024, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. Read SEC document |
| December 16, 2024 Filed Dec 18, 2024 21:57 UTC |
Novara Mark DavidEVP & CHIEF COMMERCIAL OFFICER
|
Tax withholdingCommon Stock | 10,732 | $32.66 | $350,507.12 |
DisclosureSEC source: 0001438133-24-000221 · wk-form4_1734559026.xml · nonDerivative · entry 2 Novara Mark David · CIK 0002000342 · EVP & CHIEF COMMERCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,458 F1 · kind: Shares withheld by Tandem Diabetes Care, Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold. Read SEC document |
| December 16, 2024 Filed Dec 18, 2024 21:57 UTC |
Novara Mark DavidEVP & CHIEF COMMERCIAL OFFICER
|
Exercise / conversionCommon Stock | 29,658 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-24-000221 · wk-form4_1734559026.xml · nonDerivative · entry 1 Novara Mark David · CIK 0002000342 · EVP & CHIEF COMMERCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,190 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 16, 2024 Filed Dec 18, 2024 21:56 UTC |
Carpenter RickChief Technology Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 406 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-24-000220 · wk-form4_1734559002.xml · derivative · entry 3 Carpenter Rick · CIK 0001513889 · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,624 Underlying: Common Stock · 406 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Awarded on December 15, 2021 pursuant to the Tandem Diabetes Care, Inc. 2013 Stock Incentive Plan, as amended, and the agreements related thereto (the 2013 Plan). F3 · derivative.exercise_price: Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2013 Plan. F4 · derivative.exercise_date: RSU vest as to twenty-five percent (25%) of the total number of shares subject to the RSU on 12/15/2022, and the remaining shares shall vest in twelve (12) equal quarterly installments thereafter. F4 · derivative.expiration_date: RSU vest as to twenty-five percent (25%) of the total number of shares subject to the RSU on 12/15/2022, and the remaining shares shall vest in twelve (12) equal quarterly installments thereafter. Read SEC document |
| December 16, 2024 Filed Dec 18, 2024 21:56 UTC |
Carpenter RickChief Technology Officer
|
Tax withholdingCommon Stock | 145 | $32.66 | $4,735.70 |
DisclosureSEC source: 0001438133-24-000220 · wk-form4_1734559002.xml · nonDerivative · entry 2 Carpenter Rick · CIK 0001513889 · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,935 F1 · shares: Shares withheld by Tandem Diabetes Care, Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold. Read SEC document |
| December 16, 2024 Filed Dec 18, 2024 21:56 UTC |
Carpenter RickChief Technology Officer
|
Exercise / conversionCommon Stock | 406 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-24-000220 · wk-form4_1734559002.xml · nonDerivative · entry 1 Carpenter Rick · CIK 0001513889 · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,080 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 21, 2024 Filed Nov 22, 2024 21:08 UTC |
BLICKENSTAFF KIM DDirector
|
SaleCommon Stock | 30,000 | $31.38 | $941,400.00 |
DisclosureSEC source: 0001438133-24-000217 · wk-form4_1732309683.xml · nonDerivative · entry 2 BLICKENSTAFF KIM D · CIK 0001238913 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 165,190 F3 · price: The price reported reflects the weighted average price per share of multiple transactions with prices per share ranging between $31.22 to $31.63. F2 · ownership.nature: The securities are held by the Kim Blickenstaff Revocable Trust dated April 15, 2010. Read SEC document |
| November 20, 2024 Filed Nov 22, 2024 21:08 UTC |
BLICKENSTAFF KIM DDirector
|
SaleCommon Stock | 10,000 | $30.00 | $300,000.00 |
DisclosureSEC source: 0001438133-24-000217 · wk-form4_1732309683.xml · nonDerivative · entry 1 BLICKENSTAFF KIM D · CIK 0001238913 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 195,190 F1 · price: The price reported reflects the weighted average price per share of multiple transactions with prices per share ranging between $30.00 to $30.01 F2 · ownership.nature: The securities are held by the Kim Blickenstaff Revocable Trust dated April 15, 2010. Read SEC document |
| November 15, 2024 Filed Nov 19, 2024 22:22 UTC |
Gasser Elizabeth AnneEVP, Chief Strategy Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 1,503 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-24-000209 · wk-form4_1732054926.xml · derivative · entry 11 Gasser Elizabeth Anne · CIK 0001866283 · EVP, Chief Strategy Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,019 Underlying: Common Stock · 1,503 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · security: Awarded on May 25, 2023 pursuant to the Tandem Diabetes Care, Inc. 2023 Long-Term Incentive Plan, as amended, and agreements related thereto (the 2023 Plan). F10 · derivative.exercise_price: Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan. F11 · derivative.exercise_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2024, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. F11 · derivative.expiration_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2024, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. Read SEC document |
| November 15, 2024 Filed Nov 19, 2024 22:22 UTC |
Gasser Elizabeth AnneEVP, Chief Strategy Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 475 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-24-000209 · wk-form4_1732054926.xml · derivative · entry 10 Gasser Elizabeth Anne · CIK 0001866283 · EVP, Chief Strategy Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 948 Underlying: Common Stock · 475 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · security: Awarded on May 25, 2022 pursuant to the 2013 Plan. F5 · derivative.exercise_price: Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2013 Plan. F8 · derivative.exercise_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2023, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. F8 · derivative.expiration_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2023, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. Read SEC document |
| November 15, 2024 Filed Nov 19, 2024 22:22 UTC |
Gasser Elizabeth AnneEVP, Chief Strategy Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 162 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-24-000209 · wk-form4_1732054926.xml · derivative · entry 9 Gasser Elizabeth Anne · CIK 0001866283 · EVP, Chief Strategy Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 325 Underlying: Common Stock · 162 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · security: Awarded on May 18, 2021 pursuant to the Tandem Diabetes Care, Inc. 2013 Stock Incentive Plan, as amended, and the agreements related thereto (the 2013 Plan). F5 · derivative.exercise_price: Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2013 Plan. F6 · derivative.exercise_date: RSU vest as to twenty-five percent (25%) of the total number of shares subject to the RSU on 5/15/2022, and the remaining shares shall vest in twelve (12) equal quarterly installments thereafter. F6 · derivative.expiration_date: RSU vest as to twenty-five percent (25%) of the total number of shares subject to the RSU on 5/15/2022, and the remaining shares shall vest in twelve (12) equal quarterly installments thereafter. Read SEC document |
| November 15, 2024 Filed Nov 19, 2024 22:22 UTC |
Gasser Elizabeth AnneEVP, Chief Strategy Officer
|
GrantCommon Stock | 619 | $15.64 | $9,681.16 |
DisclosureSEC source: 0001438133-24-000209 · wk-form4_1732054926.xml · nonDerivative · entry 7 Gasser Elizabeth Anne · CIK 0001866283 · EVP, Chief Strategy Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,988 F2 · kind: The reporting person is voluntarily reporting the acquisition of shares of common stock pursuant to the Tandem Diabetes Care, Inc. Amended and Restated 2013 Employee Stock Purchase Plan (ESPP), for the ESPP purchase period of May 16, 2024 through November 15, 2024. This transaction is also exempt under Rule 16b-3(c). Read SEC document |
| November 15, 2024 Filed Nov 19, 2024 22:22 UTC |
Gasser Elizabeth AnneEVP, Chief Strategy Officer
|
Tax withholdingCommon Stock | 87 | $27.34 | $2,378.58 |
DisclosureSEC source: 0001438133-24-000209 · wk-form4_1732054926.xml · nonDerivative · entry 6 Gasser Elizabeth Anne · CIK 0001866283 · EVP, Chief Strategy Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,369 F1 · kind: Shares withheld by Tandem Diabetes Care, Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold. Read SEC document |
| November 15, 2024 Filed Nov 19, 2024 22:22 UTC |
Gasser Elizabeth AnneEVP, Chief Strategy Officer
|
Exercise / conversionCommon Stock | 162 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-24-000209 · wk-form4_1732054926.xml · nonDerivative · entry 5 Gasser Elizabeth Anne · CIK 0001866283 · EVP, Chief Strategy Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,456 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 15, 2024 Filed Nov 19, 2024 22:22 UTC |
Gasser Elizabeth AnneEVP, Chief Strategy Officer
|
Tax withholdingCommon Stock | 254 | $27.34 | $6,944.36 |
DisclosureSEC source: 0001438133-24-000209 · wk-form4_1732054926.xml · nonDerivative · entry 4 Gasser Elizabeth Anne · CIK 0001866283 · EVP, Chief Strategy Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,294 F1 · kind: Shares withheld by Tandem Diabetes Care, Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold. Read SEC document |
| November 15, 2024 Filed Nov 19, 2024 22:22 UTC |
Gasser Elizabeth AnneEVP, Chief Strategy Officer
|
Exercise / conversionCommon Stock | 475 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-24-000209 · wk-form4_1732054926.xml · nonDerivative · entry 3 Gasser Elizabeth Anne · CIK 0001866283 · EVP, Chief Strategy Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,548 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 15, 2024 Filed Nov 19, 2024 22:22 UTC |
Gasser Elizabeth AnneEVP, Chief Strategy Officer
|
Tax withholdingCommon Stock | 804 | $27.34 | $21,981.36 |
DisclosureSEC source: 0001438133-24-000209 · wk-form4_1732054926.xml · nonDerivative · entry 2 Gasser Elizabeth Anne · CIK 0001866283 · EVP, Chief Strategy Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,073 F1 · kind: Shares withheld by Tandem Diabetes Care, Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold. Read SEC document |
| November 15, 2024 Filed Nov 19, 2024 22:22 UTC |
Gasser Elizabeth AnneEVP, Chief Strategy Officer
|
Exercise / conversionCommon Stock | 1,503 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-24-000209 · wk-form4_1732054926.xml · nonDerivative · entry 1 Gasser Elizabeth Anne · CIK 0001866283 · EVP, Chief Strategy Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,877 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 15, 2024 Filed Nov 19, 2024 22:22 UTC |
Vosseller LeighEVP & CHIEF FINANCIAL OFFICER
|
Exercise / conversionRestricted Stock Unit · Derivative | 1,503 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-24-000211 · wk-form4_1732054947.xml · derivative · entry 10 Vosseller Leigh · CIK 0001726322 · EVP & CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,019 Underlying: Common Stock · 1,503 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · security: Awarded on May 25, 2023 pursuant to the Tandem Diabetes Care, Inc. 2023 Long-Term Incentive Plan, as amended, and agreements related thereto (the 2023 Plan). F9 · derivative.exercise_price: Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan. F10 · derivative.exercise_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2024, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. F10 · derivative.expiration_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2024, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. Read SEC document |
| November 15, 2024 Filed Nov 19, 2024 22:22 UTC |
Vosseller LeighEVP & CHIEF FINANCIAL OFFICER
|
Exercise / conversionRestricted Stock Unit · Derivative | 475 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-24-000211 · wk-form4_1732054947.xml · derivative · entry 9 Vosseller Leigh · CIK 0001726322 · EVP & CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 948 Underlying: Common Stock · 475 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · security: Awarded on May 25, 2022 pursuant to the 2013 Plan. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2013 Plan. F7 · derivative.exercise_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2023, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. F7 · derivative.expiration_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2023, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. Read SEC document |
| November 15, 2024 Filed Nov 19, 2024 22:22 UTC |
Vosseller LeighEVP & CHIEF FINANCIAL OFFICER
|
Exercise / conversionRestricted Stock Unit · Derivative | 162 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-24-000211 · wk-form4_1732054947.xml · derivative · entry 8 Vosseller Leigh · CIK 0001726322 · EVP & CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 325 Underlying: Common Stock · 162 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Awarded on May 18, 2021 pursuant to the Tandem Diabetes Care, Inc. 2013 Stock Incentive Plan, as amended, and the agreements related thereto (the 2013 Plan). F4 · derivative.exercise_price: Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2013 Plan. F5 · derivative.exercise_date: RSU vest as to twenty-five percent (25%) of the total number of shares subject to the RSU on 5/15/2022, and the remaining shares shall vest in twelve (12) equal quarterly installments thereafter. F5 · derivative.expiration_date: RSU vest as to twenty-five percent (25%) of the total number of shares subject to the RSU on 5/15/2022, and the remaining shares shall vest in twelve (12) equal quarterly installments thereafter. Read SEC document |
| November 15, 2024 Filed Nov 19, 2024 22:22 UTC |
Vosseller LeighEVP & CHIEF FINANCIAL OFFICER
|
Tax withholdingCommon Stock | 537 | $27.34 | $14,681.58 |
DisclosureSEC source: 0001438133-24-000211 · wk-form4_1732054947.xml · nonDerivative · entry 6 Vosseller Leigh · CIK 0001726322 · EVP & CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,582 F1 · kind: Shares withheld by Tandem Diabetes Care, Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold. Read SEC document |
| November 15, 2024 Filed Nov 19, 2024 22:22 UTC |
Vosseller LeighEVP & CHIEF FINANCIAL OFFICER
|
Exercise / conversionCommon Stock | 1,503 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-24-000211 · wk-form4_1732054947.xml · nonDerivative · entry 5 Vosseller Leigh · CIK 0001726322 · EVP & CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,119 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 15, 2024 Filed Nov 19, 2024 22:22 UTC |
Vosseller LeighEVP & CHIEF FINANCIAL OFFICER
|
Tax withholdingCommon Stock | 170 | $27.34 | $4,647.80 |
DisclosureSEC source: 0001438133-24-000211 · wk-form4_1732054947.xml · nonDerivative · entry 4 Vosseller Leigh · CIK 0001726322 · EVP & CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,616 F1 · kind: Shares withheld by Tandem Diabetes Care, Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold. Read SEC document |
| November 15, 2024 Filed Nov 19, 2024 22:22 UTC |
Vosseller LeighEVP & CHIEF FINANCIAL OFFICER
|
Exercise / conversionCommon Stock | 475 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-24-000211 · wk-form4_1732054947.xml · nonDerivative · entry 3 Vosseller Leigh · CIK 0001726322 · EVP & CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,786 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 15, 2024 Filed Nov 19, 2024 22:22 UTC |
Vosseller LeighEVP & CHIEF FINANCIAL OFFICER
|
Tax withholdingCommon Stock | 58 | $27.34 | $1,585.72 |
DisclosureSEC source: 0001438133-24-000211 · wk-form4_1732054947.xml · nonDerivative · entry 2 Vosseller Leigh · CIK 0001726322 · EVP & CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,311 F1 · kind: Shares withheld by Tandem Diabetes Care, Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold. Read SEC document |
| November 15, 2024 Filed Nov 19, 2024 22:22 UTC |
Vosseller LeighEVP & CHIEF FINANCIAL OFFICER
|
Exercise / conversionCommon Stock | 162 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-24-000211 · wk-form4_1732054947.xml · nonDerivative · entry 1 Vosseller Leigh · CIK 0001726322 · EVP & CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,369 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 15, 2024 Filed Nov 19, 2024 22:23 UTC |
Novara Mark DavidEVP & CHIEF COMMERCIAL OFFICER
|
PurchaseCommon Stock | 532 | $23.24 | $12,363.68 |
DisclosureSEC source: 0001438133-24-000215 · wk-form4_1732054988.xml · nonDerivative · entry 1 Novara Mark David · CIK 0002000342 · EVP & CHIEF COMMERCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 532 F1 · shares: The reporting person is voluntarily reporting the acquisition of shares of common stock pursuant to the Tandem Diabetes Care, Inc. Amended and Restated 2013 Employee Stock Purchase Plan (ESPP), for the ESPP purchase period of May 16, 2024 through November 15, 2024. This transaction is also exempt under Rule 16b-3(c). Read SEC document |
| November 15, 2024 Filed Nov 19, 2024 22:23 UTC |
Carpenter RickChief Technology Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 1,437 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-24-000214 · wk-form4_1732054978.xml · derivative · entry 7 Carpenter Rick · CIK 0001513889 · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,623 Underlying: Common Stock · 1,437 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · security: Awarded on May 25, 2023 pursuant to the Tandem Diabetes Care, Inc. 2023 Long-Term Incentive Plan, as amended, and agreements related thereto (the 2023 Plan). F7 · derivative.exercise_price: Each restricted stock unit (RSU) represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan. F8 · derivative.exercise_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2024, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. F8 · derivative.expiration_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2024, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. Read SEC document |
| November 15, 2024 Filed Nov 19, 2024 22:23 UTC |
Carpenter RickChief Technology Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 596 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-24-000214 · wk-form4_1732054978.xml · derivative · entry 6 Carpenter Rick · CIK 0001513889 · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,191 Underlying: Common Stock · 596 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Awarded on May 25, 2022 pursuant to the Tandem Diabetes Care, Inc. 2013 Stock Incentive Plan, as amended, and the agreements related thereto (the 2013 Plan). F4 · derivative.exercise_price: Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2013 Plan. F5 · derivative.exercise_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2023, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. F5 · derivative.expiration_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2023, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. Read SEC document |
| November 15, 2024 Filed Nov 19, 2024 22:23 UTC |
Carpenter RickChief Technology Officer
|
GrantCommon Stock | 563 | $15.64 | $8,805.32 |
DisclosureSEC source: 0001438133-24-000214 · wk-form4_1732054978.xml · nonDerivative · entry 5 Carpenter Rick · CIK 0001513889 · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,674 F2 · kind: The reporting person is voluntarily reporting the acquisition of shares of common stock pursuant to the Tandem Diabetes Care, Inc. Amended and Restated 2013 Employee Stock Purchase Plan (ESPP), for the ESPP purchase period of May 16, 2024 through November 15, 2024. This transaction is also exempt under Rule 16b-3(c). Read SEC document |
| November 15, 2024 Filed Nov 19, 2024 22:23 UTC |
Carpenter RickChief Technology Officer
|
Tax withholdingCommon Stock | 513 | $27.34 | $14,025.42 |
DisclosureSEC source: 0001438133-24-000214 · wk-form4_1732054978.xml · nonDerivative · entry 4 Carpenter Rick · CIK 0001513889 · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,111 F1 · kind: Shares withheld by Tandem Diabetes Care, Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.